

# WHO EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS

Forty-first Report



World Health  
Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences.

To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

---

The *WHO Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO. An annual subscription to this series, comprising about six such reports, costs Sw. fr. 168.– or US\$ 151.– (Sw. fr. 128.40 or US\$ 115.– in developing countries). For further information, please contact WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int); or order online at <http://www.who.int/bookorders>).

*This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization*

**WHO Technical Report Series**

**943**

# **WHO EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS**

Forty-first Report



**World Health  
Organization**

WHO Library Cataloguing-in-Publication Data

WHO Expert Committee on Specifications for Pharmaceutical Preparations. Meeting (2006: Geneva, Switzerland)

WHO Expert Committee on Specifications for Pharmaceutical Preparations: forty-first report.

(WHO technical report series; no. 943)

"The WHO Expert Committee on Specifications for Pharmaceutical Preparations met in Geneva from 16 to 20 October 2006" – Introduction.

1. Pharmaceutical preparations - standards. 2. Technology, Pharmaceutical - standards. 3. Drug industry - legislation. 4. Quality control. I. World Health Organization. II. Title. III. Series.

ISBN 978 92 4 120943 4  
ISSN 0512-3054

(NLM classification: QV 771)

© World Health Organization 2007

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, WorldHealthOrganization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [permissions@who.int](mailto:permissions@who.int)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.

Typeset in Switzerland

Printed in Switzerland

# Contents

1.	Introduction .....	1
2.	General Policy .....	4
2.1	Cross-cutting pharmaceuticals – quality assurance issues ...	4
2.2	Pharmacopoeial Discussion Group .....	7
2.3	International Conference on Harmonisation .....	7
2.4	International Conference of Drug Regulatory Authorities ....	8
3.	Quality control – specifications and tests.....	8
3.1	<i>The International Pharmacopoeia</i> (4th ed.).....	8
3.2	New monographs for inclusion in <i>The International Pharmacopoeia</i> .....	9
3.3	Dissolution test requirements .....	9
3.4	Pharmacopoeial monographs on antiretrovirals.....	10
3.5	Specifications for antimalarials.....	10
3.6	Quality specifications for antituberculosis drugs.....	11
3.7	Specifications for other medicines.....	11
4.	Quality control – International Reference Materials .....	12
4.1	International Chemical Reference Substances .....	12
4.2	Guidelines for chemical reference substances.....	12
5.	Quality control – national laboratories.....	12
5.1	External Quality Assurance Assessment Scheme .....	12
6.	Quality assurance – Good Manufacturing Practices .....	13
6.1	Biologicals.....	13
6.2	Sterile pharmaceutical products.....	13
6.3	New guidelines.....	14
7.	Quality assurance – inspection .....	14
7.1	Training modules for inspectors .....	14
8.	Quality assurance – distribution and trade related .....	14
8.1	Good distribution practices for pharmaceutical products ...	14
9.	Quality assurance – risk analysis .....	15
9.1	New approach to inspections and manufacture.....	15
10.	Quality assurance – Stability .....	16
11.	Prequalification .....	16
11.1	Prequalification of priority medicines.....	16

11.2	Ongoing quality monitoring of prequalified medicines .....	17
11.3	Prequalification of quality control laboratories.....	18
11.4	Procedure for prequalification – manufacturers of active pharmaceutical ingredients .....	18
11.5	Guidance on variations to a prequalified dossier.....	18
12.	Regulatory guidance .....	18
12.1	Medicines for children.....	18
12.2	Revision/update of the guidance on the selection of comparator pharmaceutical products for equivalence assessment.....	19
12.3	Proposal to waive in vivo bioequivalence requirements for immediate release, solid oral dosage forms .....	19
12.4	WHO Certification scheme .....	20
13.	Nomenclature and computerized systems .....	20
13.1	International Nonproprietary Names (INN) for pharmaceutical substances .....	20
13.2	WHO terminology used in quality assurance .....	20
14.	Miscellaneous .....	20
14.1	Index of pharmacopoeias .....	20
14.2	Article on the Expert Committee .....	20
14.3	Promotional materials on quality .....	21
15.	Summary and recommendations.....	21
15.1	New standards and guidelines adopted and recommended for use .....	22
15.2	Activities that should be pursued and progress reported at the next meeting of the Expert Committee.....	24
15.3	New areas of work suggested.....	25
	Acknowledgements .....	26
	Annex 1 .....	45
	<i>The International Pharmacopoeia</i> – related substances tests: dosage form monographs guidance notes.....	45
	Annex 2 .....	47
	List of available International Chemical Reference Substances and International Infrared Reference Spectra .....	47
	Annex 3 .....	59
	General guidelines for the establishment, maintenance and distribution of chemical reference substances. Revision .....	59

Annex 4 ..... 83  
Procedure for assessing the acceptability, in principle, of  
pharmaceutical products for purchase by United Nations agencies ..... 83

Annex 5 ..... 97  
Prequalification of quality control laboratories. Procedure  
for assessing the acceptability, in principle, of quality control  
laboratories for use by United Nations agencies ..... 97

Annex 6 ..... 107  
Guidance on variations to a prequalified product dossier..... 107



预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report>

